Breaking Finance News

Wedbush issued a report on Medivation Inc (NASDAQ:MDVN), lowering its target price to $66.00 today

Yesterday Medivation Inc (NASDAQ:MDVN) traded 0.22% lower at $80.39. Medivation Inc’s 50-day average is $73.40 and its two hundred day average is $58.80. With the last stock price up 37.54% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Trading volume was was up over the average, with 5,722,621 shares of MDVN changing hands over the typical 3,969,200 shares..

Stating a possible downside of -0.18%, Wedbush dropped the estimated target of Medivation Inc (NASDAQ:MDVN) to $66

Recent Performance Graphic:

Medivation Inc (NASDAQ:MDVN)

A total of 17 firms have reported on the stock. Five firms rate the stock a strong buy, six firms rate the stock a buy, 10 analyts rate the company a hold, 0 rate the stock to underperform, and lastly 0 analystsrate the company as sell with a consensus target stock price of $62.35

Medivation Inc has a one-year low of $26.41 and a 52 week high of $81.15 and has a total market value of $0.0.

Brief Synopsis About Medivation Inc (NASDAQ:MDVN)

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, and pathway which it refers to as MDV4463.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *